APM Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer...

Stats
Dzisiejszy wolumen	7 685.00
Średni wolumen	2.49M
Kapitalizacja rynkowa	23.28M
EPS	$0 ( 2024-04-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.32
ATR14	$0.0650 (1.16%)

Aptorum Group Ltd Korelacja

10 Najbardziej pozytywne korelacje
MSTR	0.943
CYTO	0.935
TNGX	0.934
NAKD	0.934
AHPI	0.93
TRIT	0.929
SIRI	0.928
IMV	0.924
TENX	0.923
JAGX	0.923

10 Najbardziej negatywne korelacje
PUCK	-0.948
THCPU	-0.947
OVLY	-0.945
BRACU	-0.942
XM	-0.939
INOD	-0.935
NCAC	-0.935
TGTX	-0.934
MCAA	-0.933
TETC	-0.932

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aptorum Group Ltd Finanse

Annual	2022
Przychody:	$1.30M
Zysk brutto:	$80 065.00 (6.18 %)
EPS:	$-14.89

FY	2022
Przychody:	$1.30M
Zysk brutto:	$80 065.00 (6.18 %)
EPS:	$-14.89

FY	2021
Przychody:	$1.54M
Zysk brutto:	$81 854.00 (5.31 %)
EPS:	$-7.94

FY	2020
Przychody:	$911 509
Zysk brutto:	$-103 514 (-11.36 %)
EPS:	$2.24

Financial Reports:

No articles found.

Aptorum Group Ltd

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.